Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China; Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan 650204, China.
Antiviral Res. 2018 Sep;157:9-17. doi: 10.1016/j.antiviral.2018.07.004. Epub 2018 Jul 3.
Chronic immune activation and systemic inflammation are underlying causes of acquired immunodeficiency syndrome (AIDS). Products of virus replication and microbial translocation, co-infection or opportunistic pathogens, and danger-associated molecular patterns have been reported to contribute to chronic immune activation and inflammation in human immunodeficiency virus type-1/simian immunodeficiency virus (HIV-1/SIV) infection or other disease. To develop new strategies and therapies for HIV-1/AIDS, we tested if the CD24 and Fc fusion protein (CD24Fc), which interacts with danger-associated molecular patterns and sialic acid binding Ig-like lectin to attenuate inflammation, can protect Chinese rhesus macaques (ChRMs) with SIV infection. We found that CD24Fc treatment decreased weight loss, wasting syndrome, intractable diarrhea, and AIDS morbidity and mortality, while it was well tolerated by SIV-infected animals. Corresponding to the elimination of intractable diarrhea, CD24Fc significantly reduced the expression of IL-6 and indoleamine 2, 3-dioxygenase-1 in peripheral blood mononuclear cell and inflammation in the ileum, colon and rectum based on the reduction of inflammatory cells, pathological scores and expression of inflammatory cytokines. Furthermore, although CD24Fc did not restore CD4 T cell number or significantly change T cell subsets or CD4 T cell activation, it maintained low levels of plasma soluble CD14, CD8 T cell activation, viral load and proviral load in the peripheral blood mononuclear cells and marrow. These results suggested that CD24Fc confers protection to SIV-infected ChRMs against progression to AIDS. It was also implied that CD24Fc may be a potential therapeutic approach for the control of HIV-1/AIDS.
慢性免疫激活和全身炎症是获得性免疫缺陷综合征(AIDS)的根本原因。病毒复制产物、微生物易位、合并感染或机会性病原体以及危险相关分子模式已被报道有助于人类免疫缺陷病毒 1/猿猴免疫缺陷病毒(HIV-1/SIV)感染或其他疾病中的慢性免疫激活和炎症。为了开发针对 HIV-1/AIDS 的新策略和疗法,我们测试了 CD24 和 Fc 融合蛋白(CD24Fc)是否可以保护感染 SIV 的中国猕猴(ChRMs)。CD24Fc 与危险相关分子模式和唾液酸结合免疫球蛋白样凝集素相互作用,可减轻炎症。我们发现,CD24Fc 治疗可减轻体重减轻、消瘦综合征、难治性腹泻和 AIDS 发病率和死亡率,而感染 SIV 的动物可耐受 CD24Fc。与难治性腹泻的消除相对应,CD24Fc 显著降低了外周血单个核细胞中 IL-6 和吲哚胺 2,3-双加氧酶-1 的表达,并降低了回肠、结肠和直肠的炎症,这是基于炎症细胞、病理评分和炎症细胞因子的表达减少。此外,尽管 CD24Fc 并未恢复 CD4 T 细胞数量,也未显著改变 T 细胞亚群或 CD4 T 细胞活化,但它维持了外周血单个核细胞和骨髓中血浆可溶性 CD14、CD8 T 细胞活化、病毒载量和前病毒载量的低水平。这些结果表明,CD24Fc 可保护 SIV 感染的 ChRMs 免受 AIDS 进展。这也暗示 CD24Fc 可能是控制 HIV-1/AIDS 的潜在治疗方法。